NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I remember things being a bit strange around then, but you might scroll down and look at the 19th prelude, or even the 12th.

flipper44 Member Level Thursday, 01/28/16 10:35:14 AM
Re: None
Post # of 56291
Irish Accent: Ya Don't say now Adam? "This week" you "spoke with Celldex" Adam? Now you're sure that didn't also happen a wee bit before January 21, 2016 at 2:51 p.m.? Did you get anymore baseball tickets then Adam? No....probably not this time.

Well, let's hear what you have to say for yourself.

Quote:


I also spoke with Celldex management this week. Their point -- and it's a good one -- is that longer follow-up is required for some cancer immunotherapies like Rintega to demonstrate a meaningful survival benefit. That's because it takes time for the patient's immune system to mount a response against the cancer. Celldex won't view a decision by data monitors to continue the ACT IV study to be a negative. They believe the final analysis, if the study goes that far, still carries a good shot at a positive outcome.

Do you believe Celldex's argument supports Rintega? You have been bullish on the company and the drug in the past.

Celldex has Rintega data to back up their point. In the "REACT" study involving patients with recurrent GBM, the survival benefit demonstrated by Rintega increased in statistical significance with longer follow up. Celldex presented those data at two medical meetings last year. The REACT study supports the theory of a "long tail" of survival favoring Rintega.

If the same trend holds up in the ACT IV study, it's entirely possible the final analysis could return with a statistically significant and clinically meaningful survival benefit for Rintega.

Possible, but probable?

I have been bullish on Celldex and Rintega because the company has presented data from previous studies (like REACT) which, to me, make a convincing and supportive case for the drug benefitting GBM patients. Celldex has much more credibility than Northwest Biotherapeutics [What a bunch of malarkey Adam], which excels at promotional claims about its GBM immunotherapy but can't support any of them with convincing clinical data.

But I concede my optimism for Rintega and the outcome of the ACT IV study conflicts with the skepticism I heard from investors this week. [Investors opinions Adam??? You sure that wasn't company opinion prior to 2:51 p.m. on January 21st Adam?] That bearishness is reflected in the sharp decline in Celldex's stock price leading up to the interim analysis results. Biotech investors are not in a believing mood these days. Very few, if any, biotech companies are getting the benefit of the doubt. -- Adam Feuerstein

Thursday, 01/28/16 01:02:27 PM
Re: dlangend_02 post# 51954
Post # of 56291
Uh, this is new confirmation.

Quote:
An interim survival analysis of the Rintega "ACT IV" study is being conducted right now. -- From today -- Adam Feuerstein


The question is when did he confirm it, what else did he know, and was it before 2:51 p.m. EST, January 21, 2016?

I'm thinking it's his little mystery stock.

flipper44 Member Level Friday, 01/29/16 02:29:54 PM
Re: sentiment_stocks post# 52018
Post # of 56291
Maybe he had confirmed information even earlier. Say a week earlier. Say before 2:51 pm EST on January 21, 2016. How much info did he have then? Perhaps then he had all these after the fact publicized meetings -- perhaps that's where he wants you and others to start looking -- and not before 2:51 pm EST on January 21, 2016. Hmmm... How could we tell what his mystery stock was? He still wants us to guess.

flipper44 Member Level Friday, 01/29/16 03:09:15 PM
Re: flipper44 post# 52019
Post # of 56291
And look what AF did 2 days before that January 21, 2016 tweet at 2:51 pm EST.

Quote:
flipper44 Member Level Tuesday, 01/19/16 01:00:18 PM
Re: None
Post # of 52026
The Street's AF states Celldex's Rindopepimut Second Interim Potential Success is the number 1 thing that could turn the biotech sector around.

The Street is pumping?

You mean a therapy that treats a subclass of GBM is the number one thing that could help turn biotech's slump around?

flipper44 Member Level Monday, 02/01/16 09:47:23 AM
Re: A deleted message
Post # of 56291
On the 19th you wrote an article entitled:

Quote:
8 Things That Could Lift Biotech Stocks Out of Bear Market


On the 24th it was republished, but stated it had been originally published on the 21st and not the 19th.

Quote:
ByAdam FeuersteinFollow| 01/24/16 - 02:00 PM EST
Editors' pick: Originally published Jan. 21.


In the article(s) you list CLDX in first out of eight as the biotech that is most likely to turn biotech around.

Why is it the original publication date of your article was made to look changed from the 19th to the 21st?

-----
Regarding neoantigens:


Quote:
monentum2play Tuesday, 01/12/16 01:46:10 PM
Re: None
Post # of 52207
Adam on twitter Adam FeuersteinVerified account ?@adamfeuerstein 17m17 minutes ago
Adam Feuerstein Retweeted STAT
Good story about neoantigen cancer vaccines. Super early. But read between lines, understand why $NWBO is doomed. Adam Feuerstein added,


Quote:
flipper44 Member Level Tuesday, January 12, 2016 2:14:12 PM
Re: monentum2play post# 50505 Post # of 52207
Adam does not know DCVax-l targets neoantigens. It's ironic his misunderstanding is the exact reason DCVax is likely to succeed.
Respond | View Replies (1)


One minute later you wrote:

Quote:
Adam_Feuerstein Tuesday, January 12, 2016 2:15:41 PM
Re: flipper44 post# 50506 Post # of 52207
No, DCVax does not target neo-antigens. Whoever told you that is ignorant or lying.
Respond | View Replies (4)


I responded

Quote:
flipper44 Member Level Tuesday, January 12, 2016 2:22:48 PM
Re: Adam_Feuerstein post# 50507 Post # of 52207
Dr. Liau and Dr. Prins wrote it. Read all of post 47760.
Respond | View Replies (1)


You then did not return to the board for 14 days.